What is PEPG's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.18B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PEPG?

P/E (TTM) is n/a and 52-week range is $1.31 to $7.80 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PEPG figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PEPG?

The company profile lists net income (TTM) near $-90M, EPS (TTM) near $-1.30 when available from the market-data feed. Figures are informational and may lag live markets.

Where is PepGen Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 69.2M shares outstanding, ISIN US7133171055 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

PepGen Inc

$PEPG

Health Care · Biotechnology

IR Run Scenarios

$2.62

+10.08%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Employees

Website

pepgen.com

IPO

2022-05-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)